LeMaitre Vascular to Present at Upcoming Investor Conferences
LeMaitre Vascular (Nasdaq: LMAT) announced its participation in three investor conferences throughout September 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
LeMaitre Vascular (Nasdaq: LMAT) announced its participation in three investor conferences throughout September 2020. JJ Pellegrino, CFO, will engage in the Barrington Research Virtual Fall Investment Conference on September 9, followed by a presentation at the Cantor Virtual Global Healthcare Conference on September 15 at 4:00 PM EDT. Pellegrino will also present at the Sidoti Virtual Investor Conference on September 23 at 10:45 AM EDT. LeMaitre specializes in devices for treating peripheral vascular disease, impacting over 200 million globally.
Details
News Market Reaction – LMAT
The recorded move for LMAT in the trading session of this news was +1.86%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in three investor conferences in September.
JJ Pellegrino, Chief Financial Officer, is scheduled to participate in the 13th Annual Barrington Research Virtual Fall Investment Conference on Wednesday, September 9, 2020.
David Roberts, President, is scheduled to present at Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020, at 4:00 PM EDT.
JJ Pellegrino, Chief Financial Officer, is scheduled to present at the Sidoti Virtual Investor Conference on Wednesday, September 23, 2020, at 10:45 AM EDT.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at www.lemaitre.com.
Contact: LeMaitre Vascular, Inc. Sandra Millar +1-781-425-1686
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.